TCRT February 2012

category image Volume 11
No.1 (1-104)
February 2012
ISSN 1533-0338

Impact of Dose Hot Spots on Spinal Cord Tolerance Following Stereotactic Body Radiotherapy: A Generalized Biological Effective Dose Analysis (35-40)

The purpose of this study was to investigate the effects of high-dose inhomogeneous irradiation to small volumes of spinal cord with a new generalized biological effective dose (gBED) analysis for spine stereotactic body radiotherapy (SBRT). The gBED was applied to spinal cord dosimetric data (contoured per the thecal sac) at specified volumes for a cohort of five patients with radiation-induced myelopathy (RM) and compared to nineteen patients without RM post-SBRT. The spinal cord gBED was calculated and normalized to a conventional 2-Gy equivalent dose fraction scheme (α/β 5 2 Gy for late toxicity). Differences between the conventional BED and those gBED calculations by accounting for small-volume dosing within the spinal cord was observed. Statistically significant differences in the mean gBED between the RM group and the non-RM group was observed both at the maximum point volume (gBED of 66 Gy vs. 37 Gy (p 5 0.01), respectively) and at the 0.1 cm3 volume (gBED of 53 Gy vs. 28 Gy (p 5 0.01), respectively). No significant difference at the 0.1 cm3 volume was observed based on the mean BED comparisons. No significant differences were observed at the larger 1 cm3, 2 cm3 or 5 cm3 volumes for either BED or gBED comparisons. We conclude that differences in dose hot spots characteristics within small inhomogenously irradiated volumes of spinal cord can affect spinal cord tolerance following SBRT treatments.

Key words: Myelopathy; Radiation tolerance; Stereotactic body radiotherapy; Biologic effective dose; Biological modeling.

This article can be cited as:
A Sahgal, L Ma, J Fowler, V Weinberg, I Gibbs, PC Gerszten, S Ryu, S Soltys, E Chang, CS Wong, DA Larson. Impact of Dose Hot Spots on Spinal Cord Tolerance Following Stereotactic Body Radiotherapy: A Generalized Biological Effective Dose Analysis Technol Cancer Res Treat. 11, 35-40 (2012).

A. Sahgal, M.D.1
L. Ma, Ph.D.*
J. Fowler, D.Sc., Ph.D.3
V. Weinberg, Ph.D.4
I. Gibbs, M.D.5
P. C. Gerszten, M.D.6
S. Ryu, M.D.7
S. Soltys, M.D.5
E. Chang, M.D.8
C. S. Wong, M.D.9
D. A. Larson, M.D., Ph.D.2

1Department of Radiation Oncology, Sunnybrook Health Sciences Centre and the Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
2Department of Radiation Oncology, University of California San Francisco, San Francisco, California, USA
3Department of Human Oncology and Medical Physics, University of Wisconsin, Madison, USA
4University of California San Francisco Helen Diller Family Comprehensive Cancer Center Biostatistics Core, San Francisco, California, USA
5Department of Radiation Oncology, Stanford University, Stanford, California, USA

lma001@gmail.com

Purchase Downloadable Article

Corporate User

$100.00

University/Academic User

$50.00


Member Login | Home | Editorial Board | Instructions | Subscribe | Contact Us

Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA
phone: 518-456-0784; fax: 518-452-4955; email: info@adeninepress.com
copyright © Adeninepress, All rights reserved.